Enanta Pharmaceuticals (ENTA) Cash from Operations Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.34% |
| Dec 31, 2025 | 4.71% |
| Sep 30, 2025 | 15.94% |
| Jun 30, 2025 | 42.62% |
| Mar 31, 2025 | -23.89% |
| Dec 31, 2024 | -27.42% |
| Sep 30, 2024 | -26.33% |
| Jun 30, 2024 | -50.93% |
| Mar 31, 2024 | -24.16% |
| Dec 31, 2023 | -23.09% |
| Sep 30, 2023 | -22.53% |
| Jun 30, 2023 | -58.29% |
| Mar 31, 2023 | -12.71% |
| Dec 31, 2022 | -58.75% |
| Sep 30, 2022 | -17.83% |
| Jun 30, 2022 | -43.91% |
| Mar 31, 2022 | -54.44% |
| Dec 31, 2021 | -44.13% |
| Sep 30, 2021 | -58.13% |
| Jun 30, 2021 | -69.45% |
| Mar 31, 2021 | -19.68% |
| Dec 31, 2020 | -20.08% |
| Sep 30, 2020 | -45.45% |
| Jun 30, 2020 | 20.58% |
| Mar 31, 2020 | -31.72% |
| Dec 31, 2019 | 33.27% |
| Sep 30, 2019 | 30.14% |
| Jun 30, 2019 | -40.89% |
| Mar 31, 2019 | 56.15% |
| Dec 31, 2018 | 48.22% |
| Sep 30, 2018 | 67.85% |
| Jun 30, 2018 | 21.83% |
| Mar 31, 2018 | -22.47% |
| Dec 31, 2017 | -13.39% |
| Sep 30, 2017 | 104.39% |
| Jun 30, 2017 | -4.61% |